Plus   Neg

Stock Alert: Immunomedics Stock Up 8% On Positive Results From Phase 3 ASCENT Study Of TRODELVY

Shares of Immunomedics Inc. (IMMU) are currently trading at $40.67, up $3.13 or 8.34%, after the company announced that the confirmatory Phase 3 ASCENT study of Trodelvy met its primary endpoint of progression-free survival or PFS, as well as key secondary endpoints in brain metastasis negative patients with mTNBC who have previously received at least two prior therapies for metastatic disease.

The stock has been trading in the range of $8.80 - $41.04 for the past one year. Trading volume totaled 1.11 million versus an average volume of 5.24 million shares.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT